Compare Citius Pharmaceuticals Inc (CTXR) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Wheaton Precious Metals Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Wheaton Precious Metals Corp trades at $138 (market cap $61.17B). The key difference: Wheaton Precious Metals Corp is far larger — about 4491.2× Citius Pharmaceuticals Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Wheaton Precious Metals Corp for 66 Days on average.
| CTXR | WPM | |
|---|---|---|
Market Cap | $13.62M | $61.17B |
Volume | 132,438 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $165.72 |
52-Week Low | $0.48 | $94.37 |
Typical Hold Time | 16 Days | 66 Days |
Enterprise Value | $3.79M | $63.05B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Wheaton Precious Metals (WPM) trades at $133.69, down 2.88% today, amid a bearish technical signal. The stock shows strong fundamentals with record 2025 revenue of $2.31B and net income of $1.47B, driven by high margins and consistent earnings beats. Recent news highlights expansion plans targeting 1.2M ounces by 2030, supported by a robust deal pipeline. Analyst consensus remains strongly bullish with an 80% buy rating and a $164.80 price target, suggesting significant upside from current levels despite near-term technical weakness.
The outlook for WPM is positive due to strong earnings growth, high profitability, and strategic streaming acquisitions. Risks include exposure to gold/silver price volatility, execution of growth targets, and macroeconomic factors like interest rates. With solid cash flow and institutional support, the stock presents a compelling long-term opportunity, though investors should monitor commodity cycles and operational milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
